

## State of Oklahoma SoonerCare

## $\mathsf{Iwilfin}^{^\mathsf{TM}}$ (eflornithine) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
Pharmacy Billing (NDC:	Start Date (or date of next dose):	
Dose:	Regimen:	
Pharmacy Information		
Pharmacy NPI:	Pharmacy Name:	
Pharmacy Phone:	Pharmacy Fax:	
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	_ Prescriber Fax:	Specialty:
Criteria Criteria		
anti-GD2 immunothera C. Will eflornithine be use Yes No D. Member's body surface  Other  Additional Information:	apy? Yes No ed as a single agent to reduce e area (BSA):	or multiagent, multimodality therapy including ce the risk of relapse for a maximum of 2 years?  Date taken:
For Continued Authorization:		
If yes, please specify adverse	of progressive disease whi adverse drug reactions relactions:	ile on eflornithine? Yes No ated to eflornithine therapy? Yes No
I certify that the indicated treatment is med	dically necessary and all inform	Date: ation is true and correct to the best of my knowledge.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

processing delays.

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

## CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm-259 1/5/2024